Last reviewed · How we verify
Famitinib Malate Plus Anti-PD1 Therapy (SHR-1210) in Advanced Renal Cell Carcinoma, Urothelial Carcinoma, Advanced Cervical Cancer, Relapse Ovarian Cancer, Endometrial Cancer: Multi-institutional, Open-label, Phase 2 Trial
Phase II multi-chort, adaptive two-stage, open label, nonrandomized study. The aim of our study is to evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210(Camrelizumab) in combination with a small-molecule multikinase inhibitor Famitinib in subjects with advanced RCC/UC/CC/EC and recurrent OC. chort1: Renal Cell Carcinoma (RCC) chort2: Urothelial Carcinoma(UC) chort3: Ovarian Cancer (OC) chort4: Cervical Cancer (CC) chort5: Endometrial Cancer (EC)
Details
| Lead sponsor | Jiangsu HengRui Medicine Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 265 |
| Start date | 2019-01-23 |
| Completion | 2022-12 |
Conditions
- Renal Cell Carcinoma
- Urothelial Carcinoma
- Cervical Cancer
- Ovarian Cancer Recurrent
- Endometrial Cancer
Interventions
- SHR-1210
- Famitinib
Primary outcomes
- Overall response rate (ORR) — Up to 2 years
Defined as complete or partial response per RECIST 1.1 criteria with assessment every 9 weeks
Countries
China